These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1498869)

  • 1. The selective effects of serotonin reuptake inhibitors.
    Montgomery SA
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():353A-354A. PubMed ID: 1498869
    [No Abstract]   [Full Text] [Related]  

  • 2. Serotonin selectivity for obsessive compulsive and panic disorders.
    Montgomery SA; Bullock T; Fineberg N
    J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):30-5. PubMed ID: 1931935
    [No Abstract]   [Full Text] [Related]  

  • 3. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder.
    Fineberg NA; Bullock T; Montgomery DB; Montgomery SA
    Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():43-7. PubMed ID: 1517558
    [No Abstract]   [Full Text] [Related]  

  • 5. Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder.
    Benkert O; Wetzel H; Szegedi A
    Int Clin Psychopharmacol; 1993 Sep; 8 Suppl 1():3-14. PubMed ID: 8254151
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic potential of serotonin antagonists in depressive disorders.
    Wood MD; Thomas DR; Watson JM
    Expert Opin Investig Drugs; 2002 Apr; 11(4):457-67. PubMed ID: 11922855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obsessive-compulsive disorder.
    Zetin M; Kramer MA
    Hosp Community Psychiatry; 1992 Jul; 43(7):689-99. PubMed ID: 1516899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The place of obsessive compulsive disorder in the diagnostic hierarchy.
    Montgomery SA
    Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():19-23. PubMed ID: 1517551
    [No Abstract]   [Full Text] [Related]  

  • 9. A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety.
    Murphy DL; Pigott TA
    J Clin Psychiatry; 1990 Apr; 51 Suppl():53-8; discussion 59-60. PubMed ID: 2139026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of depersonalization with serotonin reuptake blockers.
    Hollander E; Liebowitz MR; DeCaria C; Fairbanks J; Fallon B; Klein DF
    J Clin Psychopharmacol; 1990 Jun; 10(3):200-3. PubMed ID: 2115893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the quality of care for depressed patients with comorbid psychiatric disorders: a review.
    Dunner DL
    Clin Perform Qual Health Care; 1997; 5(1):11-5. PubMed ID: 10164994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin: it's possible to have too much of a good thing.
    Stahl SM
    J Clin Psychiatry; 1997 Dec; 58(12):520-1. PubMed ID: 9448653
    [No Abstract]   [Full Text] [Related]  

  • 13. Selective serotonin reuptake inhibitors in OCD.
    Montgomery SA; Bullock T; Fineberg N; Montgomery D
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():255A-256A. PubMed ID: 1498831
    [No Abstract]   [Full Text] [Related]  

  • 14. Bibliometric analysis of biomedical publications on SSRI during 1980-2000.
    López-Muñoz F; Alamo C; Rubio G; García-García P; Martín-Agueda B; Cuenca E
    Depress Anxiety; 2003; 18(2):95-103. PubMed ID: 12964177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of comorbid mood, anxiety, and substance use disorders.
    Brady KT; Verduin ML
    Subst Use Misuse; 2005; 40(13-14):2021-41, 2043-8. PubMed ID: 16282091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of sertraline: a review.
    Heym J; Koe BK
    J Clin Psychiatry; 1988 Aug; 49 Suppl():40-5. PubMed ID: 3045112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder.
    Zak JP; Miller JA; Sheehan DV; Fanous BS
    J Clin Psychiatry; 1988 Aug; 49 Suppl():23-9. PubMed ID: 3045108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders.
    Blier P; de Montigny C
    Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):91S-98S. PubMed ID: 10432494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation with buspirone: a review.
    Harvey KV; Balon R
    Ann Clin Psychiatry; 1995 Sep; 7(3):143-7. PubMed ID: 8646275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data.
    Wylie ME; Miller MD; Shear MK; Little JT; Mulsant BH; Pollock BG; Reynolds CF
    J Geriatr Psychiatry Neurol; 2000; 13(1):43-8. PubMed ID: 10753007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.